Fluifort 2.7 g - granules mucus relief - 10 bags

Product Description

Active ingredients

1 5 g sachet contains: active ingredient: carbocisteine ​​lysine salt monohydrate equal to 2.7 g of carbocisteine ​​lysine salt Excipients: aspartame For the full list of excipients, see section 6.1.

Excipients

Citric acid, mannitol, povidone, natural cedar flavoring, natural orange flavoring, orange juice, aspartame, maltodextrin.

Therapeutic indications

Mucolytic, fluidifying in acute and chronic respiratory tract conditions.

Contraindications

Hypersensitivity to the active ingredient or to any of the excipients. Gastroduodenal ulcer. Pregnancy and breastfeeding. The drug is contraindicated in pediatric patients (under 11 years of age).

Dosage

Only 1 sachet per day. Given the pharmacokinetic characteristics, the recommended dosage can also be maintained in patients with renal and hepatic insufficiency. Duration of treatment: carbocisteine ​​lysine salt monohydrate can also be used for prolonged periods; in this case, it is advisable to follow your doctor's advice. Instructions for use of the sachet: dissolve the contents of the sachet in about half a glass of water, stirring well.

Warnings and precautions

There are no known phenomena of habituation or dependence. Fluifort 2.7 g granules for oral solution do not affect low-calorie or controlled diets and can also be administered to diabetic patients. Fluifort 2.7 g granules for oral solution do not contain gluten; therefore, they can be administered to patients with celiac disease. Fluifort 2.7 g granules for oral solution contain aspartame as a sweetener: this substance is contraindicated in subjects with phenylketonuria. Dissolve the contents of the sachet in about half a glass of water, stirring well.

Interactions

In controlled clinical studies, no interactions have been highlighted with the most common drugs used in the treatment of upper and lower respiratory tract conditions, nor with foods or laboratory tests.

Undesirable effects

The undesirable effects that may occur with Fluifort, classified by system organ class (SOC), are the following: Skin and subcutaneous tissue disorders: skin rash, urticaria, erythema, exanthema, bullous exanthema/erythema, pruritus, angioedema, dermatitis. Gastrointestinal disorders: abdominal pain, nausea, vomiting, diarrhea. Nervous system disorders: dizziness. Respiratory, thoracic, and mediastinal disorders: dyspnea. Vascular disorders: flushing.

Pregnancy and breastfeeding

Although the active substance is neither teratogenic nor mutagenic and has not shown any negative effects on reproductive function in animals, Fluifort should not be administered during pregnancy (see 4.3). Since no data are available on the passage of carbocisteine ​​lysine salt monohydrate into breast milk, use during breastfeeding is contraindicated (see 4.3).